Royalties must be paid to Medtronic, who is pursuing patent litigation against NuVasive. The court’s ruling for phase one of the litigation is significantly less than the rates requested by Medtronic. The companies settled phase two, which involved cervical plates.
NuVasive’s initial estimated royalty litigation expense was $11 million for 2013, and the new rates will increase the cost to approximately $16 million. The company plans to “aggressively appeal” the verdict.
More Articles on Devices:
Drs. John Aldridge & Scott Dunitz Implant Exactech Hip Replacement System
Pioneer Surgical Releases Minimally Invasive Spinal Fixation Device
40 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in May
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
